Last day of trading with warrants of series TO6 in Prolight Diagnostics is today, May 28, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
Annual general meeting of Prolight Diagnostics AB (publ) on 27 May 2024
The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 27 May 2024 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdx.com. The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]
Prolight on track for clinical performance studies
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announces today that their latest data for troponin in whole blood confirm that the company is now ready to initiate trials with patient samples. The latest data were generated in whole blood samples on the final commercial cartridge design, which now includes internal cartridge quality controls […]
Prolight initiates trial at London hospital Trust supported by an NIHR i4i PDA grant
Prolight Diagnostics today announces the company will initiate a trial at Guy’s and St Thomas’NHS Foundation Trust and King’s College London to pre-validate assay and prototype performance of the Psyros™ POC system. The trial is supported by the recently awarded NIHR i4i PDA grant. Initial data with patient samples will be generated in Q3 2024 […]
The exercise period for warrants of series TO6 in Prolight Diagnostics begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
Prolight Diagnostics publishes quarterly report Q1, 2024
Financial overview First quarter, January 1 – March 31, Q1 2024 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to SEK 68 (39) thousand. The profit after tax amounted to SEK -8,929 (-7,580) thousand. Earnings per share before and after dilution: […]
Prolight Diagnostics awarded SEK17M UK government grant in collaboration with leading UK hospital Trust
Prolight Diagnostics, developer of the digital point-of-care platform PsyrosTM, has been awarded an NIHR Invention for Innovation (i4i) Product Development Award (PDA) of SEK17M (£1.26M) in collaboration with among others, Guy’s and St Thomas’ NHS Foundation Trust, and King’s College London. “We are delighted to have been awarded this prestigious grant. The National Institute for […]
The exercise price for the warrants of series TO6 in Prolight Diagnostics has been determined to SEK 0.10 per share
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight selects MDx CRO for the clinical performance studies for Psyros™
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has appointed MDx CRO as its contract research partner for the clinical performance study to validate the Psyros™ high-sensitivity troponin test. After a rigorous selection process, Prolight is pleased to announce the appointment of MDxCRO as its clinical partner. The collaboration will focus on the clinical validation […]
Prolight Diagnostics AB (publ) publishes annual report for 2023
Prolight Diagnostics AB (publ) announces that the annual report for 2023 is now available on the company’s website, https://prolightdx.com/en/investors/financial-reports/ in the attached appendix. For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges […]
